SIBN News and Press, SI-BONE Inc. From 04/29/24

SANTA CLARA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 BofA Securities Healthcare Conferen...

SANTA CLARA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy today announced it will report financial results for the first quarter of 2024 after market close on Monday, May...

2024-04-14 17:56:08 ET More on Boston Scientific, CONMED, etc. ResMed: Not A Sleeper Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific: The Market's Newest Mega-Cap Needs A Breather Mizuho sees ResMed as 'overwhelming ben...

2024-03-28 16:30:02 ET Piper Sandler analyst issues BUY recommendation for SIBN on March 28, 2024 03:00PM ET. The previous analyst recommendation was Buy. SIBN was trading at $16.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2024-03-28 08:15:07 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SIBN on March 28, 2024 05:46AM ET. SIBN was trading at $15.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 1 -...

2024-03-05 02:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SANTA CLARA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Barclays 26th Annual Global Healthcare C...

2024-02-27 11:30:02 ET Truist Financial analyst issues BUY recommendation for SIBN on February 27, 2024 10:00AM ET. The previous analyst recommendation was Buy. SIBN was trading at $17.92 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...

SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Qu...

SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...